Show simple item record

dc.contributor.authorPrabhat K. Sinha
dc.contributor.authorPaul Roddy
dc.contributor.authorPedro Pablo Palma
dc.contributor.authorAlice Kociejowski
dc.contributor.authorMaría Angeles (Nines) Lima
dc.contributor.authorVidya Nand Rabi Das
dc.contributor.authorJitendra Gupta
dc.contributor.authorNawin Kumar
dc.contributor.authorGaurab Mitra
dc.contributor.authorJean-François Saint-Sauveur
dc.contributor.authorSiju Seena
dc.contributor.authorManica Balasegaram
dc.contributor.authorFernando Parreño
dc.contributor.authorKrishna Pandey
dc.date.accessioned2010-10-29T13:51:51Z
dc.date.available2010-10-29T13:51:51Z
dc.date.issued2010-08
dc.identifier.citationAm. J. Trop. Med. Hyg., 83(2), 2010, pp. 357–364en
dc.identifier.issn00029637
dc.identifier.doi10.4269/ajtmh.2010.10-0156
dc.identifier.urihttp://hdl.handle.net/10144/114066
dc.description.abstractWe evaluated, through the prospective monitoring of 251 patients at Sadar Hospital in Bihar, India, the effectiveness and safety of 20 mg/kg body weight of liposomal amphotericin B for the treatment of visceral leishmaniasis. The treatment success rates for the intention-to-treat, per protocol, and intention-to-treat worse-case scenario analyses were 98.8%, 99.6%, and 81.3%, respectively. Nearly one-half of patients experienced mild adverse events, but only 1% developed serious but non–life-threatening lips swelling. The lost to follow-up rate was 17.5%. Our findings indicate that the 20 mg/kg body weight treatment dosage is effective and safe under routine program conditions. Given that the exorbitant cost of liposomal amphotericin B is a barrier to its widespread use, we recommend further study to monitor and evaluate a lowered dosage and a shorter treatment course.
dc.language.isoenen
dc.publisherThe American Society of Tropical Medicine and Hygieneen
dc.rightsPublished by: American Society of Tropical Medicine and Hygiene, [url]http://www.ajtmh.org[/url] Archived on this site with the kind permission of the American Society of Tropical Medicine and Hygiene, [url]http://www.astmh.org[/url]en
dc.titleEffectiveness and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis under Routine Program Conditions in Bihar, Indiaen
dc.typeArticleen
dc.contributor.departmentMedecins Sans Frontieresen
dc.identifier.journalAmerican Journal of Tropical Medicine and Hygieneen
refterms.dateFOA2019-03-04T08:23:50Z
html.description.abstractWe evaluated, through the prospective monitoring of 251 patients at Sadar Hospital in Bihar, India, the effectiveness and safety of 20 mg/kg body weight of liposomal amphotericin B for the treatment of visceral leishmaniasis. The treatment success rates for the intention-to-treat, per protocol, and intention-to-treat worse-case scenario analyses were 98.8%, 99.6%, and 81.3%, respectively. Nearly one-half of patients experienced mild adverse events, but only 1% developed serious but non–life-threatening lips swelling. The lost to follow-up rate was 17.5%. Our findings indicate that the 20 mg/kg body weight treatment dosage is effective and safe under routine program conditions. Given that the exorbitant cost of liposomal amphotericin B is a barrier to its widespread use, we recommend further study to monitor and evaluate a lowered dosage and a shorter treatment course.


Files in this item

Thumbnail
Name:
Effectiveness and Safety of ...
Size:
449.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record